Aaron Goldman Bio

Aaron is an Operating Partner at BroadOak where he supports the firm’s investing activities, diligence, and portfolio companies focused on complex biological models and cell therapy. Prior to BroadOak, Aaron held senior positions at clinical-stage therapeutics companies and led product development R&D at several biotools companies focused on oncology. Aaron founded and served as CEO of Transporter Therapeutics, an AstraZeneca-partnered start-up company, that he led to an exit in 2022. Aaron has written over 80 scientific and research publications and is an author on 12 patents and patent applications related to drug development and diagnostics platforms. Aaron is an active faculty member at Harvard Medical School, a member of Cancer Immunology at the Dana-Farber Cancer Institute. He is also the founder of the Drug Resistance Group at Mass General Brigham. He received his Ph.D. in Cancer Biology and Medical Pharmacology from the University of Arizona and performed his post-doctoral fellowship at Harvard Medical School.